Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.